Coherus BioSciences Inc (CHRS) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $1.69
• Market Cap: $251.11M
• P/E Ratio: 3.05
• EPS: $0.55
• 52-Week High: $2.62
• 52-Week Low: $0.71

Market Sentiment

Coherus BioSciences Inc currently has a Neutral sentiment score of 0.06.

About Coherus BioSciences Inc

Coherus BioSciences Inc. is an innovative biopharmaceutical company focused on developing and commercializing biosimilars and cutting-edge immuno-oncology therapies, primarily in the U.S. market. Headquartered in Redwood City, California, Coherus is dedicated to expanding patient access to high-quality biologic therapies while effectively lowering healthcare expenses. With a strong product pipeline and strategic partnerships, the company is well-positioned to meet the increasing demand for co...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Coherus BioSciences Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does CHRS pay dividends?

Coherus BioSciences Inc (CHRS) does not currently pay a regular dividend.

What is CHRS's P/E ratio?

Coherus BioSciences Inc has a price-to-earnings (P/E) ratio of 3.05.

What is CHRS's market cap?

Coherus BioSciences Inc (CHRS) has a market capitalization of $251.11M with a current stock price of $1.69.